Myeloproliferative Disorders-Research Consortium (MPD-RC) MPD-RC 103 Phase II Study of Bevacizumab (Avastin) in Myelofibrosis.

Trial Profile

Myeloproliferative Disorders-Research Consortium (MPD-RC) MPD-RC 103 Phase II Study of Bevacizumab (Avastin) in Myelofibrosis.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Jun 2015

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Myelofibrosis
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 06 Dec 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
    • 06 Dec 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Oct 2008 Integrated M.D Anderson site information for this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top